Login
$EXEL
$65.99 -$1.11 (1.65%) After hours

$EXEL SEC Filings

Filed On Filing
09 Nov 2026 SCHEDULE 13G
09 Nov 2026 SCHEDULE 13D/A
29 Oct 2026 10-Q
29 Oct 2026 8-K: Results of Operations and Financial Condition

ALAMEDA, Calif. – October 29, 2026 - Exelixis, Inc. (Nasdaq: EXEL) today reported financial results for the third quarter of 2026, provided an update on progress toward achieving key corporate objectives, and outlined its commercial, cli...

11 Sep 2026 8-K: Other Events

Today, Exelixis, Inc. (Exelixis) announced that on September 10, 2026, the U.S. Food and Drug Administration (FDA) notified Exelixis that it had extended the review period for Exelixis’ new drug application (NDA) for zanzalintinib, in co...

31 Aug 2026 8-K: Other Events

On August 31, 2026, Exelixis, inc. (Exelixis) announced that the U.S. Court of Appeals for the Federal Circuit (Court of Appeals) issued a decision in Exelixis, Inc. v. MSN Laboratories Private Limited et al., Appeal No. 25-1236, affirmi...

14 Aug 2026 SCHEDULE 13D/A
12 Aug 2026 Form 4: Beckerle Mary C, Director

Sold 9,812 shares ($527K)

12 Aug 2026 SCHEDULE 13G/A
10 Aug 2026 144
05 Aug 2026 S-8
05 Aug 2026 10-Q
05 Aug 2026 8-K: Results of Operations and Financial Condition

ALAMEDA, Calif. – August 5, 2026 - Exelixis, Inc. (Nasdaq: EXEL) today reported financial results for the second quarter of 2026, provided an update on progress toward achieving key corporate objectives, and outlined its commercial, clin...

03 Jun 2026 Form 4: Wyszomierski Jack L, Director

Sold 3,925 shares ($198K)

03 Jun 2026 Form 4: Eckhardt Sue Gail, Director

Sold 9,812 shares ($492K)

01 Jun 2026 144
01 Jun 2026 144
29 May 2026 Form 4: Papadopoulos Stelios, Director

Received 8,367 shares as a grant or award

29 May 2026 Form 4: Heyman Tomas J., Director

Received 8,367 shares as a grant or award

29 May 2026 Form 4: Eckhardt Sue Gail, Director

Received 8,367 shares as a grant or award

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Premium Feature

This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.

Premium includes:

  • Unlimited historical financial data
  • Advanced analytics and insights
  • Priority support